Celanese Corporation Q2 FY2026 earnings call

Core Strategic Priorities

• Maintain three overarching corporate priorities: 1) Increase free cash flow and aggressively deleverage the balance sheet; 2) Intensify cost improvements and ongoing productivity gains; 3) Drive top-line growth in high-value, fast-growing end-market sub-segments aligned with the firm's unique capabilities.
• Maintain the $1 billion total divestiture target by the end of 2027; the firm is halfway to this target after closing the Micromax transaction, and management expects to announce at least one additional divestiture deal by the end of 2026.

Operational Highlights

• The firm's global supply chain network delivered strong resiliency in the quarter, particularly supporting reliable supply to customers in supply-impacted regions like Europe.
• The accelerated closure of the Linnokin (AC segment) plant was completed earlier than originally anticipated, pulling forward associated inventory absorption costs into 2026 H2.
• The Frankfurt plant, which had been idled for over six months, was brought back online in just five weeks to meet customer demand, demonstrating strong operational agility.
• The EM business successfully implemented targeted price increases in Q2 to offset rising raw material costs, exiting the quarter at a strong price level that offsets much of the expected raw material cost pressure in H2 2026.
• The pace of destocking in the acetate tow sub-segment slowed considerably in Q2, with order patterns beginning to normalize relative to 2025 levels.
• The Ibnsina joint venture, which did not operate for most of Q2, has resumed operations in Q3 2026 and is expected to ramp up through Q4.

Growth Strategy

• EM's "Grow and Fortify" strategy focuses on penetrating high-margin, high-growth sub-segments rather than chasing low-value volume. Key growth areas include AI data centers, medical/ drug delivery, and electronics.
• AI data center servers create 3x the material opportunity for Selenese compared to traditional servers, driven by demand for signal protection, speed, and thermal management materials across connectors, thermal systems, and wire and cable applications.
• GLP-1 and other at-home injectable drug delivery is a large, growing market, and the firm's $500 million total addressable market estimate already contemplates the expected growth of GLP-1 pills.
• In automotive, the firm prioritizes gaining share in high-value growth areas like electric drive units over matching overall industry volume growth, aligning its capacity with its shift to higher-value mix.

The call does not disclose full absolute revenue or net income figures for the company's two core segments, but provides the following operational and margin performance details:

1. Acetyl Chain (AC) Segment: Volumes were flat year-over-year in Q2 2026. Acetate tow sub-segment volumes declined year-over-year due to ongoing customer destocking, offsetting volume gains in the binals chain. Over 80% of the segment's long-term profitability is generated in the Western Hemisphere, a dynamic that held in the quarter. Asia margins returned to pre-war levels by mid-Q2 2026 after a short period of upward movement earlier in the year, while Western Hemisphere margins remain above pre-war levels. The segment captured incremental market share in the quarter due to its reliable supply amid ongoing industry supply chain disruptions.
2. Engineering Materials (EM) Segment: Excluding divestitures, overall segment volumes were flattish year-over-year in Q2 2026. Auto volumes declined a few percentage points year-over-year, tracking lower industry vehicle build levels, while non-auto volumes increased. High-margin growth sub-segments already contribute meaningful revenue and margin: electronics accounts for 10% of segment revenue and 10-15% of segment contribution margin; medical accounts for less than 10% of segment revenue and 20% of segment contribution margin. The segment delivered double-digit year-over-year adjusted EBIT growth in 2026 year-to-date, growing at ~15% after absorbing $45 million in inventory absorption costs from nylon optimization and $35 million in adjusted EBIT loss from the completed Micromax divestiture. The segment achieved targeted pricing increases in Q2 to offset rising raw material costs, driving margin expansion in the quarter.

• Management reaffirmed the full-year 2026 earnings guidance of $6 per share, originally issued in May. Q2 2026 outperformed the original guidance slightly, with the incremental benefit offset by expected lower Q3 results driven by earlier-than-planned plant closures, pulled-forward inventory absorption costs, and lower-than-anticipated equity earnings from the Ibnsina joint venture (expected to be $10 million lower than original guidance for the full year).
• Full-year 2026 free cash flow guidance of $700 million to $800 million is reaffirmed, with management confident in this range. This range is viewed as the baseline sustainable free cash flow level for the firm over the next several years.
• Q3 2023 earnings guidance is set at $1.35 to $1.75 per share.
• Annualized cost savings from completed restructuring actions are expected to be $50 million from nylon optimization and $20 to $25 million from the Linnokin plant closure. One-third of the Linnokin savings and half of the nylon restructuring savings will be realized in H2 2026, with the full benefit realized in 2027. Total annualized cost reductions entering 2027 are expected to be $80 to $100 million, which will offset potential macro moderation next year.
• Management expects working capital for full-year 2026 to be between neutral (zero) and slightly positive, after a $300 million year-to-date use of cash for working capital as of Q2, which will normalize in H2.
• Management targets reducing net debt to ~$10 billion by the end of 2026, and to ~$9 billion by the end of 2027. The long-term leverage target is 3x net debt to EBITDA, with the next near-term milestone being 4x net debt to EBITDA.
• Management expects the pace of earnings moderation in H2 2026 to be in line with original expectations, with no material upward or downward revision to the anticipated trajectory.

• Ongoing supply chain volatility remains a key operating risk, particularly amid ongoing dislocations in global acetyl markets.
• Raw material prices have been volatile in 2026, creating the risk of margin compression in EM in Q3 2026 as higher raw material costs flow through the business, even after Q2 pricing actions.
• Persistent destocking in the acetate tow sub-segment is expected to continue into H2 2026, weighing on near-term sales and earnings.
• Geopolitical volatility in the region of the Ibnsina joint venture creates uncertainty around the pace of the expected ramp up in equity earnings in the second half of 2026.
• Further macroeconomic moderation could pressure margins and volumes across both business segments in 2027, though planned cost reductions are expected to offset much of this impact.

Q: How does the current supply environment for the acetyl chain compare to management's earlier expectations, and what is driving recent spread increases in Asia? / A: The pace of supply moderation in H2 2026 is still in line with what management expected when it issued full-year guidance in May. Q2 outperformed original guidance in part due to emerging market pre-buying, but Q3 will be slightly lower than originally guided because of the accelerated Linnokin plant closure and pulled-forward inventory absorption, plus a $10 million full-year hit to equity earnings from the idled Ibnsina JV, almost all of which hits Q3. Recent upward movement in Asia spreads has not changed the broader trajectory of margins returning to pre-war levels by mid-Q2.

Q: What is the current base size, growth outlook, and strategy for the high-growth sub-segments that are the focus of EM's "Grow and Fortify" strategy? / A: Currently, electronics makes up 10% of EM revenue and 10-15% of EM contribution margin, while medical makes up less than 10% of revenue and 20% of contribution margin. While broad macro end markets for EM have low overall growth, deep dives reveal high-growth niche pockets where Selenese can leverage its unique capabilities. Management is reorienting the commercial team to prioritize penetrating these higher-margin sub-segments for sustainable long-term growth.

Q: What is the timeline for the $1 billion divestiture target, and are there additional plant rationalization plans after the recently announced closures? / A: The $1 billion divestiture target by the end of 2027 remains unchanged; Selenese is halfway there after closing the Micromax transaction, and management expects to announce at least one more deal by the end of 2026. After completing the larger recent footprint actions, any future rationalization will likely be smaller, in the $5 million to $10 million annual savings range per site, and will shift more to supply chain efficiency and inventory reduction rather than full plant closures, as the firm focuses on strengthening its global specialty compounding leadership.

Q: Why were acetyl chain volumes flat year-over-year in Q2, even with available capacity and competitor outages? What were the auto and non-auto volume growth trends in EM for the quarter? / A: Acetyl volumes were flat because volume gains in the binals chain were fully offset by lower year-over-year volumes in acetate tow, which is still facing ongoing customer destocking. For EM (excluding divestitures), overall volumes were flattish year-over-year. Auto volumes declined a few percentage points, matching lower industry vehicle build levels, and this decline was offset by volume growth in all non-auto end markets.